Bronfman E.L. Rothschild L.P. increased its stake in shares of AstraZeneca plc (NYSE:AZN) by 440.7% in the 4th quarter, HoldingsChannel.com reports. The firm owned 26,303 shares of the company’s stock after purchasing an additional 21,438 shares during the period. Bronfman E.L. Rothschild L.P.’s holdings in AstraZeneca were worth $913,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently modified their holdings of AZN. Russell Investments Group Ltd. lifted its holdings in shares of AstraZeneca by 198.9% during the third quarter. Russell Investments Group Ltd. now owns 1,856,140 shares of the company’s stock worth $62,883,000 after purchasing an additional 1,235,239 shares during the period. Hardman Johnston Global Advisors LLC acquired a new stake in shares of AstraZeneca during the fourth quarter worth $35,125,000. Sector Gamma AS acquired a new stake in shares of AstraZeneca during the third quarter worth $25,094,000. Janus Henderson Group PLC lifted its holdings in shares of AstraZeneca by 5,754.0% during the third quarter. Janus Henderson Group PLC now owns 726,599 shares of the company’s stock worth $24,617,000 after purchasing an additional 714,187 shares during the period. Finally, Point72 Asset Management L.P. lifted its holdings in shares of AstraZeneca by 103.1% during the third quarter. Point72 Asset Management L.P. now owns 1,224,939 shares of the company’s stock worth $41,501,000 after purchasing an additional 621,831 shares during the period. 14.75% of the stock is owned by hedge funds and other institutional investors.

Shares of AstraZeneca plc (NYSE:AZN) opened at $34.09 on Tuesday. AstraZeneca plc has a fifty-two week low of $28.43 and a fifty-two week high of $36.70. The company has a debt-to-equity ratio of 0.93, a current ratio of 0.80 and a quick ratio of 0.62. The company has a market capitalization of $84,760.00, a price-to-earnings ratio of 28.89, a price-to-earnings-growth ratio of 2.03 and a beta of 0.74.

AstraZeneca (NYSE:AZN) last released its earnings results on Friday, February 2nd. The company reported $1.30 EPS for the quarter, beating analysts’ consensus estimates of $0.44 by $0.86. AstraZeneca had a return on equity of 36.38% and a net margin of 21.83%. The company had revenue of $5.78 billion during the quarter, compared to the consensus estimate of $5.49 billion. During the same quarter last year, the company earned $1.21 earnings per share. AstraZeneca’s quarterly revenue was up 3.4% compared to the same quarter last year. equities research analysts expect that AstraZeneca plc will post 1.67 EPS for the current year.

The firm also recently announced a semiannual dividend, which will be paid on Monday, March 19th. Shareholders of record on Friday, February 16th will be issued a $0.95 dividend. This represents a yield of 5.62%. The ex-dividend date of this dividend is Thursday, February 15th. AstraZeneca’s dividend payout ratio (DPR) is currently 116.10%.

Several equities research analysts recently weighed in on AZN shares. Credit Suisse Group raised AstraZeneca from a “neutral” rating to an “outperform” rating in a report on Monday, October 16th. Cowen reaffirmed a “hold” rating and set a $37.00 price target on shares of AstraZeneca in a report on Tuesday, October 17th. Citigroup raised AstraZeneca to a “buy” rating in a report on Wednesday, October 18th. Leerink Swann increased their price target on AstraZeneca from $31.00 to $34.00 and gave the stock a “market perform” rating in a report on Monday, October 23rd. Finally, BMO Capital Markets set a $38.00 price target on AstraZeneca and gave the stock a “buy” rating in a report on Tuesday, October 31st. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. AstraZeneca has an average rating of “Hold” and an average target price of $35.20.

WARNING: This piece was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of US & international copyright legislation. The original version of this piece can be read at https://theolympiareport.com/2018/02/13/bronfman-e-l-rothschild-l-p-buys-21438-shares-of-astrazeneca-plc-azn.html.

About AstraZeneca

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca plc (NYSE:AZN).

Institutional Ownership by Quarter for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.